A randomized, double-blind, split-faced study comparing A.I. Clearing Treatment with 0.1% adapalene versus 0.1% adapalene in treatment of mild to moderate degree acne vulgaris

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20171031005

Enrollment

Registered

2017-10-31

Start date

2017-11-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild to moderate degree acne vulgaris acne vulgaris acne adapalene glycolic acid salicylic acid gluconolactone licochalcone A moisture A.I. Clearing Treatment

Interventions

A.I. Clearing Treatment with 0.1% adapalene that already combined in one tube. Apply to one side of cheek at face (side A),0.1% adapalene Apply to one side of cheek at face (side B)

Active Comparator Drug,Placebo Comparator Drug

A.I. Clearing Treatment with 0.1% adapalene , 0.1% adapalene

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. Male or female, 18-40 years old 2. Mild to moderate acne vulgaris by Acne Consensus Conference (ACC) criteria

Exclusion criteria

Exclusion criteria: 1. previous phototherapy/laser within 4 weeks or use topical/systemic for treat acne within 2 2. who has other skin lesion or skin disease in study area 3. pregnancy or lactation 4. allergy to adapalene, glycolic acid, salicylic acid, gluconolactone, licochalcone A 5. immunocompromised host 6. psychiatric problem

Design outcomes

Primary

Measure	Time frame
inflammatory lesions of acne 0, 1, 2, 4 weeks counting	—

Secondary

Measure	Time frame
erythema (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),scale (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),burning (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),itching (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),transpeidermal water loss 0, 1, 2, 4 weeks TewameterÂ®,skin hydration 0, 1, 2, 4 weeks CorneometerÂ®,acne grading 0, 1, 2, 4 weeks Acne Consensus Conference (ACC),radiance visual analog scale 0, 1, 2, 4 weeks visual analog scale (VAS) for degree of sleepiness,Investigatorâ€™s Global Assessment Acne (IGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5),Patientâ€™s Global Assessment Acne (PGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5)	—

Measure

Time frame

erythema (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),scale (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),burning (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),itching (side effect) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4),transpeidermal water loss 0, 1, 2, 4 weeks TewameterÂ®,skin hydration 0, 1, 2, 4 weeks CorneometerÂ®,acne grading 0, 1, 2, 4 weeks Acne Consensus Conference (ACC),radiance visual analog scale 0, 1, 2, 4 weeks visual analog scale (VAS) for degree of sleepiness,Investigatorâ€™s Global Assessment Acne (IGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5),Patientâ€™s Global Assessment Acne (PGA) 0, 1, 2, 4 weeks Likert scale (0, 1, 2, 3, 4, 5)

—

Countries

Thailand

Contacts

Public ContactPravit Asawanonda

Faculty of Medicine, Chulalongkorn University

fibrosis@gmail.com022564253

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

A randomized&#44; double&#45;blind&#44; split&#45;faced study comparing A.I. Clearing Treatment with 0.1% adapalene versus 0.1% adapalene in treatment of mild to moderate degree acne vulgaris